Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.49 |
| ▸ | MMP12 | P39900 | 4/20 | 0.47 |
| ▸ | MMP7 | P09237 | 3/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP10 | P09238 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611773 | 0.91 | USP30 (0.62) | USP30KDM4EPKMDGAT2ADAM17 | |
| SCHEMBL23464149 | 0.88 | USP30 (0.55) | USP30KDM4EPKMDGAT2ADAM17 | |
| SCHEMBL16032849 | 0.87 | USP30 (0.60) | USP30KDM4EPKMDGAT2ADAM17 | |
| SCHEMBL16032847 | 0.87 | USP30 (0.60) | USP30KDM4EPKMDGAT2ADAM17 | |
| SCHEMBL9199101 | 0.86 | USP30 (0.57) | USP30DGAT2ADAM17MMP12MMP7 | |
| SCHEMBL9196648 | 0.86 | USP30 (0.57) | USP30DGAT2ADAM17MMP12MMP7 | |
| SCHEMBL9199093 | 0.86 | USP30 (0.57) | USP30DGAT2ADAM17MMP12MMP7 | |
| SCHEMBL505031 | 0.84 | USP30 (0.50) | USP30KDM4EPKMDGAT2ADAM17 | |
| SCHEMBL120242 | 0.84 | USP30 (0.64) | USP30KDM4EPKMRORCNAMPT | |
| SCHEMBL23464253 | 0.82 | USP30 (0.64) | USP30KDM4EPKMDGAT2ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315768-B1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-08-09 | — | — | EP | disclosed |
| US-8637491-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2014-01-28 | — | — | US | disclosed |
| US-20110172191-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172191-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP2K2, MAP2K1, MAP2K3 | USP30 2621/4885KDM4E 1493/4885PKM 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.